MDL Over Claims Relating Incretin Mimetics to Pancreatic Cancer to Proceed

MDL Over Claims Relating Incretin Mimetics to Pancreatic Cancer to Proceed
Feb 2, 2018 Gayle Gerling Pettinga Read Time: < 1 minute

Litigation against incretin mimetics producers for the product’s link to pancreatic cancer in Type 2 Diabetics is expected to proceed as an MDL.

After many years of working its way through the court system, the United States Court of Appeals for the Ninth Circuit reversed a lower court’s decision. The appeals court ruled that the trial court should have more thoroughly considered information about the drug. 

Next steps for the MDL are currently under consideration.

Source: The National Law Review

By: Gayle Gerling Pettinga

Born and raised in Evansville, Gayle is a respected, experienced lawyer and a valued community leader. She graduated near the top of her class at Indiana University’s prestigious Maurer School of Law. She’s practiced law with one of the largest firms in Indianapolis as well as one of the largest pharmaceutical companies in the world. And that means she knows how big law firms and big companies think and how they operate – and she will put that knowledge to work for you.

Gayle has received numerous awards and honors including Martindale-Hubbell — Peer Review Rated: AV®, American Institute of Personal Injury Attorneys 10 Best Attorneys in Indiana for Exceptional and Outstanding Client Service, and YWCA Evansville 100 Years, 100 Women Honoree, 2011.

(888) 437-5464
Jump to a Topic  Schedule Your Free Consultation